Literature DB >> 15008833

Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications.

S H Song1, P M Brown.   

Abstract

AIMS: To assess differences between absolute coronary heart disease (CHD) risks calculated by Joint British Societies (JBS) risk calculator and UKPDS risk engine and its impact on CHD primary prevention management in diabetes mellitus (DM).
METHODS: Seven hundred Type 2 DM patients without arterial complications were identified from nine general practices in the Scarborough area. Their absolute 10-year CHD risks were calculated. The differences in the proportion of patients identified for aspirin and statin under JBS and National Institute for Clinical Excellence (NICE) guidelines by these two methods were determined. The proportion of additional patients identified for statin in the Scarborough population as a consequence of CHD risk threshold reduction from 30 to 15% (as recommended by NICE) was also determined.
RESULTS: UKPDS risk engine calculated significantly higher mean 10-year CHD risk (UKPDS vs. JBS, 21.5 vs. 18.3%, P < 0.0001). Both methods identified approximately 65% of patients to be eligible for aspirin and statin if NICE recommendations were followed. At a risk threshold of 30%, the UKPDS risk engine identified more patients for statin. Reducing the CHD risk threshold from 30 to 15% for statin initiation will identify an additional 0.5% of the total population for this treatment.
CONCLUSIONS: Both methods are comparable in identifying at-risk patients under NICE recommendations. A high proportion has risk levels that merits primary CHD prevention. Lowering the risk threshold for statin treatment has a small numerical impact on the whole population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15008833     DOI: 10.1111/j.1464-5491.2004.01116.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  15 in total

1.  Clinical trials report. Metabolic effects of carvedilol versus metoprolol in patients with type 2 diabetes mellitus and hypertension.

Authors:  Kathleen H Berecek; David Calhoun
Journal:  Curr Hypertens Rep       Date:  2005-06       Impact factor: 5.369

2.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.

Authors: 
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

3.  Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019.

Authors:  Dalton Bertolim Précoma; Gláucia Maria Moraes de Oliveira; Antonio Felipe Simão; Oscar Pereira Dutra; Otávio Rizzi Coelho; Maria Cristina de Oliveira Izar; Rui Manuel Dos Santos Póvoa; Isabela de Carlos Back Giuliano; Aristóteles Comte de Alencar Filho; Carlos Alberto Machado; Carlos Scherr; Francisco Antonio Helfenstein Fonseca; Raul Dias Dos Santos Filho; Tales de Carvalho; Álvaro Avezum; Roberto Esporcatte; Bruno Ramos Nascimento; David de Pádua Brasil; Gabriel Porto Soares; Paolo Blanco Villela; Roberto Muniz Ferreira; Wolney de Andrade Martins; Andrei C Sposito; Bruno Halpern; José Francisco Kerr Saraiva; Luiz Sergio Fernandes Carvalho; Marcos Antônio Tambascia; Otávio Rizzi Coelho-Filho; Adriana Bertolami; Harry Correa Filho; Hermes Toros Xavier; José Rocha Faria-Neto; Marcelo Chiara Bertolami; Viviane Zorzanelli Rocha Giraldez; Andrea Araújo Brandão; Audes Diógenes de Magalhães Feitosa; Celso Amodeo; Dilma do Socorro Moraes de Souza; Eduardo Costa Duarte Barbosa; Marcus Vinícius Bolívar Malachias; Weimar Kunz Sebba Barroso de Souza; Fernando Augusto Alves da Costa; Ivan Romero Rivera; Lucia Campos Pellanda; Maria Alayde Mendonça da Silva; Aloyzio Cechella Achutti; André Ribeiro Langowiski; Carla Janice Baister Lantieri; Jaqueline Ribeiro Scholz; Silvia Maria Cury Ismael; José Carlos Aidar Ayoub; Luiz César Nazário Scala; Mario Fritsch Neves; Paulo Cesar Brandão Veiga Jardim; Sandra Cristina Pereira Costa Fuchs; Thiago de Souza Veiga Jardim; Emilio Hideyuki Moriguchi; Jamil Cherem Schneider; Marcelo Heitor Vieira Assad; Sergio Emanuel Kaiser; Ana Maria Lottenberg; Carlos Daniel Magnoni; Marcio Hiroshi Miname; Roberta Soares Lara; Artur Haddad Herdy; Cláudio Gil Soares de Araújo; Mauricio Milani; Miguel Morita Fernandes da Silva; Ricardo Stein; Fernando Antonio Lucchese; Fernando Nobre; Hermilo Borba Griz; Lucélia Batista Neves Cunha Magalhães; Mario Henrique Elesbão de Borba; Mauro Ricardo Nunes Pontes; Ricardo Mourilhe-Rocha
Journal:  Arq Bras Cardiol       Date:  2019-11-04       Impact factor: 2.000

Review 4.  The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  R Kahn; J Buse; E Ferrannini; M Stern
Journal:  Diabetologia       Date:  2005-09       Impact factor: 10.122

Review 5.  Approaches to prevention of cardiovascular complications and events in diabetes mellitus.

Authors:  Sergio Coccheri
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.

Authors:  R R Holman; S Paul; A Farmer; L Tucker; I M Stratton; H A W Neil
Journal:  Diabetologia       Date:  2008-11-11       Impact factor: 10.122

7.  Estimation of absolute cardiovascular risk in individuals with diabetes mellitus: rationale and approaches.

Authors:  Justin B Echouffo-Tcheugui; Modele O Ogunniyi; André P Kengne
Journal:  ISRN Cardiol       Date:  2011-11-23

8.  Comparison of the Framingham Risk Score, UKPDS Risk Engine, and SCORE for Predicting Carotid Atherosclerosis and Peripheral Arterial Disease in Korean Type 2 Diabetic Patients.

Authors:  Hye-Ran Ahn; Min-Ho Shin; Woo-Jun Yun; Hye-Yeon Kim; Young-Hoon Lee; Sun-Seog Kweon; Jung-Ae Rhee; Jin-Su Choi; Seong-Woo Choi
Journal:  Korean J Fam Med       Date:  2011-03-31

9.  Potential modification of the UKPDS risk engine and evaluation of macrovascular event rates in controlled clinical trials.

Authors:  Fred Yang; June Ye; Kenneth Pomerantz; Murray Stewart
Journal:  Diabetes Metab Syndr Obes       Date:  2013-07-12       Impact factor: 3.168

10.  Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study.

Authors:  A Sandbaek; S J Griffin; G Rutten; M Davies; R Stolk; K Khunti; K Borch-Johnsen; N J Wareham; T Lauritzen
Journal:  Diabetologia       Date:  2008-04-29       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.